Aeryana Beaudrie-Nunn, PharmD (Twitter: @ABeaudrieRx) identifies the rationale for antithrombotic therapy following TAVR, reviews the utility of direct oral anticoagulants after TAVR considering recent clinical trial data and defines the patient context where direct oral anticoagulant use following TAVR is most appropriate.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.